Peter Park
Nurse Practitioner · Grandview, WANPI 1154937241
Payments from drug & device makers
Across 99 payments — averaging $22.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$654
- AstraZeneca$605
- Bayer$186
- Novo Nordisk$170
- Daiichi Sankyo Inc.$87
- Sanofi Pasteur Inc.$64
- plus $426 from 16 others
What the payments were for
- Food & beverage$2,193100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 27 | $654 |
| AstraZeneca | 24 | $605 |
| Bayer | 10 | $186 |
| Novo Nordisk | 9 | $170 |
| Daiichi Sankyo Inc. | 3 | $87 |
| Sanofi Pasteur Inc. | 4 | $64 |
| Lilly USA, LLC | 3 | $63 |
| Pfizer | 3 | $48 |
| Sunovion Pharmaceuticals Inc. | 2 | $45 |
| Lundbeck LLC | 2 | $34 |
| Neurocrine Biosciences, Inc. | 1 | $29 |
| Teva Pharmaceuticals USA, Inc. | 1 | $24 |
| Harmony Biosciences LLC | 1 | $22 |
| Integra Lifesciences Corporation | 1 | $21 |
| Viatris Specialty LLC | 1 | $21 |
| GSK | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Merck | 1 | $18 |
| Dexcom, Inc. | 1 | $16 |
| Cardiovascular Systems Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,193 in reported general payments places this provider in the 90th percentile of 2,466 nurse practitioner providers in Washington.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 19 | $25,672 |
| EliquisApixaban | 12 | $19,466 |
| OzempicSemaglutide | 13 | $11,950 |
| InvokanaCanagliflozin | 11 | $6,192 |
| Atorvastatin Calcium | 100 | $926 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 24 | $729 |
| Losartan Potassium | 85 | $452 |
| Omeprazole | 20 | $253 |
| Metoprolol Succinate | 24 | $239 |
| Tamsulosin Hcl | 19 | $197 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 16 | $195 |
| Lisinopril | 47 | $181 |
| Metformin Hcl ErMetformin Hcl | 28 | $149 |
| Simvastatin | 23 | $112 |
| Pioglitazone Hcl | 15 | $92 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $605 | $25,67219 claims |
| PfizerEliquis | $48 | $19,46612 claims |
| Novo NordiskOzempic | $170 | $11,95013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,466 nurse practitioner providers in Washington.
Other nurse practitioner in Grandview
- Darla ChapmanSeattle$541K
- Olga VoloshinaSeattle$279K
- Sandra ChristensenSeattle$244K
- Wayne ClarkYakima$232K
- Felicia ForrestLynnwood$206K
- Amaris MurphyBellevue$146K
- Sonia GlennieSeattle$78K
- Megan WildesTacoma$72K
- Kate KennedyBellevue$63K
- Vicki HainesPasco$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.